10-QPeriod: Q2 FY2002

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2002

Filed August 14, 2002For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported its second quarter 2002 financial results, demonstrating continued revenue growth and improved profitability compared to the prior year. The Companion Animal Group (CAG) saw a modest revenue increase, driven by strong sales of canine test kits and veterinary reference laboratory services, despite some inventory reduction at distributors impacting feline test kits and VetTest slides. The Food and Environmental Group (FEG) also experienced revenue growth, primarily from poultry and livestock testing products and water testing products. Overall, the company benefited from the adoption of new accounting standards, notably SFAS No. 142, which eliminated goodwill amortization, leading to a lower effective tax rate and improved reported net income and earnings per share. The company maintains a strong liquidity position and expects current resources to fund operations, while also highlighting ongoing product development and market expansion strategies.

Key Highlights

  • 1Revenue for the second quarter of 2002 increased to $105.7 million, up 3% from $102.0 million in the prior year's second quarter.
  • 2Net income for the second quarter of 2002 rose to $13.0 million ($0.38 per diluted share) from $10.0 million ($0.29 per diluted share) in the prior year's second quarter.
  • 3The Companion Animal Group (CAG) revenue grew 3% to $84.6 million, driven by strong canine test kit sales (SNAP® 3Dx™ up 144%) and veterinary reference lab services.
  • 4The Food and Environmental Group (FEG) revenue increased 8% to $21.1 million, primarily due to growth in poultry and livestock testing products and water testing products.
  • 5The adoption of SFAS No. 142 eliminated goodwill amortization, leading to a decrease in the effective tax rate from 36% to 34% and a reported increase in net income.
  • 6Operating expenses for CAG decreased by 13% due to the elimination of goodwill amortization, currency exchange gains, and reduced sales and marketing expenses.
  • 7The company's inventory levels decreased to $75.5 million from $86.2 million year-over-year, and distributor inventory levels were actively managed to improve supply chain efficiency.
  • 8IDEXX repurchased approximately 1.0 million shares of common stock for $29.8 million during the six months ended June 30, 2002, as part of an ongoing share repurchase program.

Frequently Asked Questions

Revenue growth was primarily driven by the Companion Animal Group (CAG), which saw increased sales of canine test kits, notably the SNAP® 3Dx™ test, and a rise in veterinary reference laboratory services. The Food and Environmental Group (FEG) also contributed with higher sales of poultry and livestock testing products and water testing products.

The adoption of SFAS No. 142, which requires testing goodwill for impairment rather than amortizing it, significantly impacted the results. This led to the cessation of goodwill amortization, a reduction in the effective tax rate from 36% to 34%, and a corresponding increase in reported net income and earnings per share.

IDEXX is actively working to reduce distributor inventory levels to create a more efficient supply chain. This strategy has led to lower inventory levels for feline test kits and VetTest slides with distributors. The company also manages specific product inventories, like nitazoxanide and VetTest slides, carefully, assessing risks of obsolescence and potential future losses based on sales forecasts and regulatory approvals.

Key risks include intense competition and rapid technological change in its markets, reliance on proprietary technologies and patent protection, potential infringement litigation, dependence on a limited number of suppliers for critical components, significant international operations subject to currency fluctuations and regulatory changes, and potential write-downs of inventory related to product development delays or regulatory non-approval, such as for the nitazoxanide product.